Congress enacts PAMA relief: Legal and compliance implications for laboratories, physician groups, and health care providers

Recent federal legislation enacted as part of the Consolidated Appropriations Act, 2026 provides temporary but meaningful relief from scheduled Medicare payment reductions under the Protecting Access to Medicare Act of 2014 (PAMA). Although time-limited, these changes carry important legal, compliance, and contracting implications for laboratories, physician groups, and other health care providers that rely on Medicare reimbursement or maintain agreements tied to the Medicare Clinical Laboratory Fee Schedule (CLFS). This alert summarizes the enacted PAMA relief and highlights why health care organizations should be paying close attention now.

Overview of Enacted PAMA Changes

The legislation makes three principal changes to the current PAMA framework.

Extension of the moratorium on CLFS rate reductions

The law extends the existing moratorium on PAMA-related CLFS rate reductions through December 31, 2026, blocking Medicare payment cuts that were otherwise scheduled to take effect in early 2026. Absent this extension, reductions of up to 15 percent on nearly 800 clinical laboratory tests would have applied during the 2026 calendar year.

Use of more recent private payor data

The legislation updates the private payor data used to calculate Medicare laboratory rates, replacing outdated historical data with payment information from January 1 through June 30, 2025. This change reflects longstanding concerns that Medicare reimbursement levels should better align with current commercial market pricing.

Revised data reporting timeline

The next PAMA data reporting period has been moved from January 1-March 31, 2026, to May 1-July 31, 2026. Applicable laboratories, therefore, have additional time to prepare, validate, and submit required private payor rate and volume data to CMS.

Why this matters from a legal and compliance perspective

PAMA reporting obligations create regulatory exposure

Even with short-term payment relief, PAMA’s reporting requirements remain in effect. Applicable laboratories must submit private payor rate and volume data to CMS during the revised 2026 reporting window. These submissions constitute regulatory filings—not voluntary disclosures—and errors, unsupported assumptions, or inconsistent methodologies can create compliance and enforcement risk.

Entities should not assume they fall outside PAMA simply because laboratory services are not their primary business line. Physician groups, health systems, and joint ventures may trigger reporting obligations depending on billing structures, revenue composition, and affiliated laboratory operations.

Contracting and reimbursement considerations

By stabilizing CLFS rates through the end of 2026, the enacted PAMA relief may affect a wide range of contractual arrangements, including:

1. Managed care contracts tied to Medicare or CLFS benchmarks;
2. Professional services agreements with reimbursement adjustment provisions; and
3. Outreach, reference laboratory, or ancillary services agreements.

Organizations should review whether the enacted PAMA delay affects pricing assumptions, renegotiation rights, notice obligations, or compliance requirements under existing agreements.

Strategic and transactional implications

For providers considering acquisitions, affiliations, or service-line expansions, temporary stabilization of CLFS rates may influence valuation, revenue projections, and deal structuring. At the same time, the limited duration of the relief underscores the importance of conservative forecasting and diligence around long-term reimbursement risk once the moratorium expires.

Recommended next steps

Health care organizations should consider taking the following actions:

1. Evaluate PAMA applicability
   Confirm whether the organization qualifies as an “applicable laboratory,” including through affiliated entities or joint ventures.
2. Plan for the 2026 reporting period
   Begin internal planning now for data collection, validation, and documentation in advance of the May–July 2026 reporting window.
3. Review Medicare-linked contracts
   Identify contracts tied to Medicare or CLFS rates and assess whether the enacted delay impacts pricing, compliance obligations, or strategic planning.
4. Strengthen governance and documentation.
   Ensure written policies, internal controls, and audit trails support defensible PAMA reporting and ongoing compliance.

Looking ahead

While the enacted legislation provides welcome short-term relief, it does not resolve broader concerns regarding PAMA’s long-term structure or its impact on laboratory reimbursement. The current moratorium on reductions expires at the end of 2026. Beginning January 1, 2027, and continuing through December 31, 2029, payment for a test may not be reduced by more than 15% per year compared to the payment amount for the preceding year. Additional legislative or regulatory activity remains likely, and health care organizations should continue to monitor developments closely while preparing for renewed reimbursement pressure.